The product passed all release criteria for infusion and was administered to the patient after lymphodepletion with fludarabine 30mg/m2 and cyclophosphamide 500mg/m2 daily for 3 days. UF-Kure19 cells expanded robustly in the patient and peaked around day 10 (23% of circulating CD3) with a strong skewing of CD4/CD8 cells (93% CD8+ T cells on day 10)...In vitro and animal data suggest this fast-manufacturing platform leads to potent CAR-T cells. Early human testing indicates CAR-T cells generated using this novel system have clinical activity against hematologic malignancies.
1 year ago
Clinical • CAR T-Cell Therapy • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
P1, N=10, Recruiting, James Michael Martin | Trial completion date: Dec 2026 --> Dec 2024 | Initiation date: Oct 2023 --> Apr 2023 | Trial primary completion date: Jun 2026 --> Jun 2024
over 1 year ago
Trial completion date • Trial initiation date • Trial primary completion date